Maggie Mullen, MD, MSCI, has been selected for funding through the Siteman Investment Program.
“The Siteman Investment Program (SIP) Research Development Award (RDA) is designed to award pilot funding to faculty investigators to support pioneering cancer research and produce data to leverage further external peer-reviewed funding” via the Siteman Research Site.
Dr. Mullen’s proposal, “Targeting COPS5 to Overcome PARP Inhibitor Resistance in Ovarian Cancer,” will begin in January 2026.
Congratulations, Dr. Mullen!